CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 77 enrolled
Drug / intervention
liposome bupivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03587636
NCT03587636Phase 2Completed

Prospective Randomized Controlled Trial Comparing Liposomal Bupivacaine to Bupivacaine Interscalene Blocks for Total Shoulder Arthroplasty Surgery; a Pilot Study

University of Minnesota·interventional·Posted Jul 16, 2018·Updated May 2, 2022

In Brief

A Phase 2 clinical trial evaluating liposome bupivacaine and Bupivacaine for Acute Pain. Completed, enrolled 77 participants across 1 site.

Detailed Summary

This is a randomized prospective outcomes study comparing two groups of patients. One group will receive liposomal bupivacaine plus bupivacaine and the other will receive bupivacaine alone in interscalene blocks when undergoing total shoulder arthroplasty. The purpose of the study is to determine if LB plus bupivacaine provides superior pain control compared to bupivacaine alone when injected in an interscalene block for patients undergoing total shoulder arthroplasty surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Pain
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 16, 2018
Enrollment StartSep 17, 2018
Primary CompletionMar 15, 2021
Study CompletionMar 17, 2021
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.0 years ago

Interventions

liposome bupivacainedrug

interscalene block with liposomal bupivacaine plus bupivacaine

Bupivacainedrug

interscalene block with bupivacaine